"Oncogenic shock": explaining oncogene addiction through differential signal attenuation
- PMID: 16857816
- DOI: 10.1158/1078-0432.CCR-06-0096
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation
Abstract
"Oncogene addiction" describes the curious acquired dependence of tumor cells on an activated oncogene for their survival and/or proliferation, a phenomenon that has important implications for the success of targeted cancer therapies. However, the mechanisms explaining oncogene addiction remain elusive. We propose that "addiction" may be an illusion generated as a consequence of differential attenuation rates of prosurvival and proapoptotic signals emanating from an oncoprotein acutely following its inactivation. According to this model, which we call "oncogenic shock," prosurvival signals dissipate quickly on oncoprotein inactivation whereas proapoptotic signals linger sufficiently long to commit the cell to an apoptotic death. This mechanism may contribute to the rapid and dramatic clinical responses observed in some cancer patients treated with selective tyrosine kinase inhibitors and could yield additional drug targets that determine the balance of signaling outputs from activated oncoproteins.
Similar articles
-
Oncogene addiction: role of signal attenuation.Dev Cell. 2006 Dec;11(6):752-4. doi: 10.1016/j.devcel.2006.11.006. Dev Cell. 2006. PMID: 17141149
-
Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?Cancer Res. 2008 May 1;68(9):3081-6; discussion 3086. doi: 10.1158/0008-5472.CAN-07-5832. Cancer Res. 2008. PMID: 18451131 Review.
-
Oncogene addiction.Cancer Res. 2008 May 1;68(9):3077-80; discussion 3080. doi: 10.1158/0008-5472.CAN-07-3293. Cancer Res. 2008. PMID: 18451130 Review.
-
Tumor dormancy and oncogene addiction.APMIS. 2008 Jul-Aug;116(7-8):629-37. doi: 10.1111/j.1600-0463.2008.01037.x. APMIS. 2008. PMID: 18834407 Review.
-
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.Cancer Cell. 2006 Nov;10(5):425-35. doi: 10.1016/j.ccr.2006.09.014. Cancer Cell. 2006. PMID: 17097564 Free PMC article.
Cited by
-
Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells.PLoS One. 2016 Jun 30;11(6):e0158395. doi: 10.1371/journal.pone.0158395. eCollection 2016. PLoS One. 2016. PMID: 27362942 Free PMC article.
-
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone.Odontology. 2012 Jul;100(2):109-29. doi: 10.1007/s10266-012-0070-5. Epub 2012 Jun 10. Odontology. 2012. PMID: 22684584 Free PMC article. Review.
-
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models.Cancers (Basel). 2013 Jul 24;5(3):901-18. doi: 10.3390/cancers5030901. Cancers (Basel). 2013. PMID: 24202326 Free PMC article.
-
Oncogene addiction: resetting the safety switch?Oncotarget. 2014 Sep 30;5(18):7986-7. doi: 10.18632/oncotarget.2474. Oncotarget. 2014. PMID: 25275297 Free PMC article. No abstract available.
-
Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.Cancer Res. 2009 Mar 15;69(6):2244-51. doi: 10.1158/0008-5472.CAN-08-3398. Epub 2009 Mar 3. Cancer Res. 2009. PMID: 19258500 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous